Company research
Liquidia Corp
CIK 1819576Updated Sep 24, 2026
SecurityLQDA · NASDAQ · equity
LQDA price & chart
Loading TradingView…
NASDAQ:LQDA on TradingView ↗About the company
Liquidia Corporation is a biopharmaceutical company driven by science and compassion to revolutionize care for patients with challenging respiratory and vascular diseases. The company's current focus spans the development and commercialization of products in pulmonary hypertension and other applications of its proprietary PRINT® Technology. PRINT enabled the creation of YUTREPIA® (treprostinil) inhalation powder, a drug approved for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). YUTREPIA is currently under development for other indications, including SSc-RP. The company is also developing L606, an investigational extended-release formulation of treprostinil administered twice daily with a next-generation nebulizer, and currently markets generic Treprostinil Injection for the treatment of PAH. To learn more about Liquidia, please visit www.liquidia.com.
In the news
Liquidia to Present Posters at the European Respiratory Society (ERS) 2026 Congress ↗
Recent filings
4 filing
Other Events
Items 8.01, 9.01
4 filing
4 filing
10-Q filing
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 327,934,000Source | 230,313,000Source | 118,332,000Source | 129,198,000Source |
| Property, Plant and Equipment, NetUSD | 11,844,000Source | 8,298,000Source | 4,480,000Source | 4,151,000Source |
| GoodwillUSD | 3,903,000Source | 3,903,000Source | 3,903,000Source | 3,903,000Source |
| Intangible Assets, Net (Excluding Goodwill)USD | 2,952,000Source | 3,156,000Source | 3,430,000Source | 3,726,000Source |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 190,680,000Source | 176,479,000Source | 83,679,000Source | 93,283,000Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | 54,093,000Source | 2,719,000Source | 4,061,000Source | 5,017,000Source |
| Inventory, NetUSD | 23,802,000Source | 241,000Source | — | — |
| Assets, CurrentUSD | 273,401,000Source | 185,105,000Source | 89,899,000Source | 99,811,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 4,826,000Source | 5,666,000Source | 2,159,000Source | 1,511,000Source |
| Operating Lease, Right-of-Use AssetUSD | 3,949,000Source | 4,187,000Source | 1,704,000Source | 2,101,000Source |
| Other Assets, NoncurrentUSD | 13,171,000Source | 10,918,000Source | — | — |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 283,186,000Source | 153,038,000Source | 71,039,000Source | 38,776,000Source |
| Stockholders’ equity: | ||||
| Common Stock, Value, IssuedUSD | 87,000Source | 85,000Source | 69,000Source | 64,000Source |
| Additional Paid in CapitalUSD | 670,974,000Source | 636,682,000Source | 476,322,000Source | 440,954,000Source |
| Retained Earnings (Accumulated Deficit)USD | -626,313,000Source | -559,492,000Source | -429,098,000Source | -350,596,000Source |
| Stockholders' Equity Attributable to ParentUSD | 44,748,000Source | 77,275,000Source | 47,293,000Source | 90,422,000Source |
| Liabilities and EquityUSD | 327,934,000Source | 230,313,000Source | 118,332,000Source | 129,198,000Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 135,768,000Source | 41,781,000Source | 18,550,000Source | 8,800,000Source |
| Operating Lease, Liability, CurrentUSD | — | — | 1,032,000Source | 900,000Source |
| Accounts Payable, CurrentUSD | 3,678,000Source | 4,689,000Source | 1,396,000Source | 2,197,000Source |
| Operating Lease, Liability, NoncurrentUSD | — | — | 2,300,000Source | 3,332,000Source |
| Additional Financial Items | ||||
| Long-term Debt, Excluding Current MaturitiesUSD | — | — | — | 19,879,000Source |
| Long-term Debt, Excluding Current MaturitiesUSD | — | — | — | 19,879,000Source |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | -68,924,000Source | -130,394,000Source | -78,502,000Source | -41,015,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Depreciation, Depletion and AmortizationUSD | 1,528,000Source | 2,197,000Source | 2,178,000Source | 3,647,000Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | 29,472,000Source | 18,806,000Source | 10,089,000Source | 9,298,000Source |
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in InventoriesUSD | 22,988,000Source | 241,000Source | — | — |
| Increase (Decrease) in Accounts PayableUSD | -2,593,000Source | 2,330,000Source | -1,152,000Source | 814,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -35,686,000Source | -93,422,000Source | -41,564,000Source | -28,588,000Source |
| Cash flows from investing activities: | ||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | -6,336,000Source | -8,441,000Source | -11,288,000Source | -587,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | 4,336,000Source | 4,949,000Source | 1,290,000Source | 592,000Source |
| Cash flows from financing activities: | ||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 59,727,000Source | 194,663,000Source | 43,248,000Source | 64,964,000Source |
| Repayments of Long-term DebtUSD | 21,090,000Source | 4,853,000Source | 20,000,000Source | 10,500,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | 17,705,000Source | 92,800,000Source | -9,604,000Source | 35,789,000Source |
| Supplemental disclosure of cash flow information: | ||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | — | — | 360,000Source | 1,626,000Source |
| Additional Financial Items | ||||
| Share-based Payment Arrangement, ExpenseUSD | 29,472,000Source | 18,806,000Source | 10,089,000Source | 9,298,000Source |
| Amortization of Intangible AssetsUSD | 200,000Source | 300,000Source | 300,000Source | 700,000Source |
| Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber PropertyUSD | -11,000Source | -46,000Source | 2,000Source | -4,000Source |
| Gain (Loss) on Extinguishment of DebtUSD | — | -4,268,000Source | -2,311,000Source | -997,000Source |
| General and Administrative ExpenseUSD | — | 81,569,000Source | 44,742,000Source | 32,411,000Source |
| GoodwillUSD | 3,903,000Source | 3,903,000Source | 3,903,000Source | 3,903,000Source |
| Income Tax Expense (Benefit)USD | 0Source | 0Source | 0Source | 0Source |
| InterestExpenseNonoperatingUSD | 24,172,000Source | 12,486,000Source | — | — |
| Investment Income, InterestUSD | 6,624,000Source | 7,654,000Source | 3,466,000Source | 1,090,000Source |
| Net Income (Loss) Attributable to ParentUSD | -68,924,000Source | -130,394,000Source | -78,502,000Source | -41,015,000Source |
| Nonoperating Income (Expense)USD | -17,548,000Source | -9,100,000Source | -5,118,000Source | -2,245,000Source |
| Proceeds from Issuance of Long-term DebtUSD | 74,975,000Source | — | — | 19,767,000Source |
| Proceeds from Stock Options ExercisedUSD | 2,971,000Source | 1,771,000Source | 495,000Source | 837,000Source |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Total RevenueUSD | 158,320,000Source | 13,996,000Source | 17,488,000Source | 15,935,000Source |
| Cost of RevenueUSD | — | 5,879,000Source | 2,888,000Source | 2,859,000Source |
| Gross Profit (Calculated) · Derived | — | — | — | — |
| Selling, General and Administrative ExpenseUSD | 157,178,000Source | — | — | — |
| Operating Income (Loss)USD | -51,376,000Source | -121,294,000Source | -73,384,000Source | -38,770,000Source |
| Income Tax Expense (Benefit)USD | 0Source | 0Source | 0Source | 0Source |
| Net Income (Loss) Attributable to ParentUSD | -68,924,000Source | -130,394,000Source | -78,502,000Source | -41,015,000Source |
| Earnings Per Share, BasicUSD per share | -0.8Source | -1.66Source | -1.21Source | -0.67Source |
| Earnings Per Share, DilutedUSD per share | -0.8Source | -1.66Source | -1.21Source | -0.67Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 86,059,101Source | 78,707,503Source | 64,993,476Source | 60,958,862Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 86,059,101Source | 78,707,503Source | 64,993,476Source | 60,958,862Source |
| Interest Expense (non-operating)USD | 24,172,000Source | 12,486,000Source | — | — |
| Additional Financial Items | ||||
| Amortization of Intangible AssetsUSD | 200,000Source | 300,000Source | 300,000Source | 700,000Source |
| Cost of Property Repairs and MaintenanceUSD | 500,000Source | 300,000Source | 300,000Source | 300,000Source |
| Costs and ExpensesUSD | 209,696,000Source | 135,290,000Source | 90,872,000Source | 54,705,000Source |
| Depreciation, Depletion and Amortization, NonproductionUSD | 900,000Source | 800,000Source | 1,200,000Source | 1,400,000Source |
| General and Administrative ExpenseUSD | — | 81,569,000Source | 44,742,000Source | 32,411,000Source |
| Interest ExpenseUSD | — | — | 6,273,000Source | 2,338,000Source |
| Investment Income, InterestUSD | 6,624,000Source | 7,654,000Source | 3,466,000Source | 1,090,000Source |
| Nonoperating Income (Expense)USD | -17,548,000Source | -9,100,000Source | -5,118,000Source | -2,245,000Source |
| Research and Development ExpenseUSD | 39,276,000Source | 47,842,000Source | 43,242,000Source | 19,435,000Source |
Filing attachments
tm2624724d1_ex99-1.htm · 8-K · 2026-09-03
EX-99.1 2 tm2624724d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 FDA Grants Fast Track Designation to YUTREPIA® for the Treatment of Raynaud's Phenomenon Associated with Systemic Sclerosis Fast Track designation underscores the significant unmet need for patients with systemic sclerosis-associated Raynaud's phenomenon (SSc-RP), a debilitating manifestation affecting up to 90% of SSc patients No therapy is currently approved in the U.S. to treat SSc-RP and management options are limited …
Read attachment ↗tm2622888d1_ex99-1.htm · 8-K · 2026-08-12
EX-99.1 2 tm2622888d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Liquidia Corporation Reports Second Quarter 2026 Financial Results YUTREPIA® (treprostinil) inhalation powder net product sales of approximately $170.4 million in the second quarter of 2026, up 31% from the first quarter of 2026 Approximately 5,900 unique patient prescriptions and more than 5,000 patients treated between launch in June 2025 and July 31, 2026 Recorded fourth consecutive quarter of increasing profit…
Read attachment ↗tm2622888d1_ex99-2.htm · 8-K · 2026-08-12
EX-99.2 3 tm2622888d1_ex99-2.htm EXHIBIT 99.2 Exhibit 99.2 ©2026 LIQUIDIA CORPORATION ALL RIGHTS RESERVED Second Quarter 2026 Earnings & Corporate Update Liquidia Corporation August 12, 2026 ────────────────────────────────────────────────── ©2026 LIQUIDIA CORPORATION ALL RIGHTS RESERVED 2 Forward-looking statements This presentation may include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained…
Read attachment ↗tm2617139d1_ex99-1.htm · 8-K · 2026-06-08
EX-99.1 2 tm2617139d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Liquidia Corporation Announces Inclusion in the S&P SmallCap 600® Index MORRISVILLE, N.C. (June 8, 2026) - Liquidia Corporation (Nasdaq: LQDA), a biopharmaceutical company driven by science and compassion to revolutionize care for patients with challenging respiratory and vascular diseases, announced today that it will be added to the S&P SmallCap 600® Index, effective prior to the opening of trading on June 22, 2026. Introduced …
Read attachment ↗tm2614109d1_ex99-1.htm · 8-K · 2026-05-11
EX-99.1 2 tm2614109d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Liquidia Corporation Reports First Quarter 2026 Financial Results YUTREPIA® (treprostinil) inhalation powder net product sales of approximately $130 million in the first quarter of 2026 More than 4,500 unique patient prescriptions and approximately 3,750 patients treated between launch in June 2025 and April 30, 2026 Recorded third consecutive quarter of profitability, with net income of approximately $53 million, adjusted …
Read attachment ↗tm2614109d1_ex99-2.htm · 8-K · 2026-05-11
EX-99.2 3 tm2614109d1_ex99-2.htm EXHIBIT 99.2 Exhibit 99.2 ©2026 LIQUIDIA CORPORATION ALL RIGHTS RESERVED First Quarter 2026 Earnings & Corporate Update Liquidia Corporation May 11, 2026 2 ©2026 LIQUIDIA CORPORATION ALL RIGHTS RESERVED Forward - looking statements This presentation may include forward - looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this presentation other than statements of historical facts, inclu…
Read attachment ↗